Skip to main content

Senolytic CAR T cells as novel therapeutic concept for solid tumors and senescence-associated diseases.

Project description

New immunotherapies for cancer and beyond

Chimeric antigen receptor (CAR) T cells are genetically engineered immune cells that destroy target cells with precision thanks to combined antigen binding and T cell activating functions. Their adaptation has enabled new treatments in patients with haematological B cell malignancies. They are very promising for other cancer types and diseases, such as senescence-associated pathologies, but limitations from the antigenic heterogeneity or impaired T cell trafficking must be solved. The EU-funded CARsen project will develop a novel therapeutic concept through the engineering of T cells against senescent cells that will be combined with therapies that induce senescence in tumour cells. The new therapy will be tested for safety and efficacy in murine models of cellular senescence and solid tumours.

Host institution

EBERHARD KARLS UNIVERSITAET TUEBINGEN
Net EU contribution
€ 1 818 637,00
Address
Geschwister-scholl-platz
72074 Tuebingen
Germany

See on map

Region
Baden-Württemberg Tübingen Tübingen, Landkreis
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,50

Beneficiaries (1)

EBERHARD KARLS UNIVERSITAET TUEBINGEN
Germany
Net EU contribution
€ 1 818 637,00
Address
Geschwister-scholl-platz
72074 Tuebingen

See on map

Region
Baden-Württemberg Tübingen Tübingen, Landkreis
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,50